

Cryptic Promoter Usage in MET


- Observed in multiple cancers for a decade
 - CML, colon, liver, bladder...




- Stable protein product in gastric CA
- Found in ~5% of KIRP samples


Translation in Gastric CA





Workflow






Methylation

- Activation of TE is a result of loss of methylation
 - The closet probe is ~3kb downstream, marginal statistically significant (p=0.055)
- Abnormal methylation
 - Enriched in methylation cluster 2 (hypermeth),p=0.05
 - Enriched in C2b (basically all type2 has meth C2), p<0.05





Population-specific AF ("popmax") ≤ 0.5% in *both* datasets



Scenario I

ClinVAR annotation:

- Risk
- Likely pathogenic
- Pathogenic

Scenario II

Scenario I

AND

Disruptive mutations:

- Rated HIGH by Ensembl
- TSL1

Scenario III

Scenario II

AND

High-impact missense:

- Polyphen score > 0.9
- TSL 1, 2 & 3

ExAC

0.7%

1.2%

4.4%

1000 Genomes 0.34%


0.42%

4.05%

Filter using 1KG

- .5% AF cutoff cross-applied to both ExAC and 1KG
 - .5% AF too restrict in sub-pop? (~1000 alleles)
 - Three SNPs has low MAFs in ExAC

	EAS	AMR	AFR	EUR	SAS	ExAC
rs554829380	0.0446	0.0375	0.0129	0.0477	0	9.06798E-05
rs45466399	С	0	0.0083	0	0	0.000408854
rs569318927	0.006	0.0058	0.0008	0.002	0	0.002291319
rs142934950	C	0.0058	0	0	0	0.000424673



Not Enriched in ExAC-TCGA

- About 12% ExAC comes from TCGA
- Need to look at RCC cohorts

	nonTCGA	TCGA
ClinVAR	0.10%	0.07%
LoF	0.20%	0.11%
ALL	4.40%	3.85%